Altered Growth Trajectory in Children Born to Mothers with Gestational Diabetes Mellitus and Preeclampsia by Huang, Yonglin et al.
City University of New York (CUNY) 
CUNY Academic Works 
Publications and Research Queens College 
2020 
Altered Growth Trajectory in Children Born to Mothers with 
Gestational Diabetes Mellitus and Preeclampsia 
Yonglin Huang 
CUNY Graduate Center 
Wei Zhang 
New Jersey City University 
Karen Go 
CUNY Graduate Center 
Kenji J. Tsuchiya 
Hanamatsu University 
Jianzhong Hu 
Icahn School of Medicine at Mount Sinai 
See next page for additional authors 
How does access to this work benefit you? Let us know! 
More information about this work at: https://academicworks.cuny.edu/qc_pubs/383 
Discover additional works at: https://academicworks.cuny.edu 
This work is made publicly available by the City University of New York (CUNY). 
Contact: AcademicWorks@cuny.edu 
Authors 
Yonglin Huang, Wei Zhang, Karen Go, Kenji J. Tsuchiya, Jianzhong Hu, Daniel W. Skupski, Sheow Yun Sei, 
and Yoko Nomura 
This article is available at CUNY Academic Works: https://academicworks.cuny.edu/qc_pubs/383 
Running head: GROWTH TRAJECTORY IN CHILDREN  1 
Manuscript word count: 3534 1 
Abstract word count: 243 2 
Tables: 2 3 
Figures: 2 4 
Date: December 4, 2019 5 
 6 
Altered growth trajectory in children born to mothers with gestational diabetes mellitus and preeclampsia 7 
 8 
Yonglin Huang2, Wei Zhang3, Karen Go2, Kenji J. Tsuchiya4, Jianzhong Hu5,6, Daniel W. Skupski7, Sheow Yun 9 
Sie1, Yoko Nomura1, 2   10 
 11 
1 Department of Psychology, Queens College, City University of New York, New York, USA 12 
2 Department of Psychology, Graduate Center, City University of New York, USA 13 
3 Department of Psychology, New Jersey City University, New Jersey, USA 14 
4Research Center for Child Mental Development and United Graduate School of Child Development, Hamamatsu 15 
University School of Medicine, Hamamatsu, Shizuoka, Japan  16 
5Icahn Institute for Data Science and Genomic Technology, Icahn School of Medicine at Mount Sinai, New York, 17 
USA 18 
6 Department of Genetics and Genomic Sciences, Icahn School of Medicine at Mount Sinai, New York, USA 19 
7 Weill Cornell Medicine, Department of Obstetrics and Gynecology, Division of Maternal-Fetal Medicine, New 20 
York Presbyterian Queens, Flushing, New York, USA 21 
 22 
Corresponding author: 23 
Yoko Nomura 24 
Queens College, CUNY 25 
Department of Psychology 26 
65-30 Kissena Blvd.  27 
Flushing, NY 11367 28 
Telephone: +1 (718) 997-3164 29 
Fax: +1 (718) 997-3257 30 





The authors would like to the families for their participation, the Stress in Pregnancy laboratory staff at Queens College 36 
CUNY (especially Jackie Finik, Westar Zong, and Victoria Kuo), and the staff at the prenatal clinics and OB/GYN 37 
departments of Icahn School of Medicine at Mount Sinai and New York Presbyterian-Queens Hospital.   38 
 39 
This research work was supported by the National Institute of Mental Health under award number R01MH102729 and the 40 
Professional Staff Congress City University of New York grant to Y Nomura. The content of the manuscript is solely the 41 







GROWTH TRAJECTORY IN CHILDREN 
 
2 
Abstract  49 
Purpose:  Gestational diabetes mellitus (GDM) and preeclampsia are leading causes of mortality and morbidity in 50 
mothers and children. High childhood body mass index (BMI) is among their myriad of negative outcomes. 51 
However, little is known about the trajectory of the child BMI exposed to GDM and co-occurring preeclampsia 52 
from early to mid-childhood. This study examined the independent and joint impact of GDM and preeclampsia on 53 
childhood BMI trajectory. Methods:  A population-based sample of 356 mothers were recruited from OB/GYN 54 
clinics in New York. Their children were then followed annually from 18 to 72 months. Maternal GDM and 55 
preeclampsia status were obtained from medical records. Child BMI was calculated based on their height and 56 
weight at annual visits. Results: Hierarchical Linear Modeling was used to evaluate the trajectories of child BMI 57 
exposed to GDM and preeclampsia. BMI trajectory by GDM decreased (t-ratio = -2.24, 𝛽=.45, 95% CI=-.05-.95, 58 
p = .07), but the trajectory by preeclampsia increased over time (t-ratio = 3.153, 𝛽=.65, 95%CI=.11-1.18, p = 59 
.002). Moreover, there was a significant interaction between the two (t-ratio = -2.24, 𝛽=-1.244, 95%CI=.15-2.33, 60 
p = .02), such that the BMI of children born to mothers with both GDM and preeclampsia showed consistent 61 
increases over time. Conclusions: GDM and preeclampsia could be used as a marker for childhood obesity risk 62 
and the identification of a high-risk group, providing potential early intervention. These findings highlight the 63 
importance of managing obstetric complications, as an effective method of child obesity prevention.  64 
 65 
Keywords:  66 
gestational diabetes mellitus, preeclampsia, childhood obesity, body mass index, growth trajectory, prenatal origin 67 
of childhood obesity 68 
  69 
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Childhood obesity, defined as body mass index (BMI) at or above the 95th percentile, is a growing problem; 70 
the United States has observed significant trend increases from 1999-2000 through 2015-2016 [1]. Recent estimates 71 
of its prevalence are approximately 17-19%, affecting approximately 13.7 million youth [1]. Risk factors for 72 
childhood obesity include early life BMI and lifestyle factors (e.g., sleep duration, lack of exercise, and poor diet) 73 
[2]. Less is known about the implication of prenatal maternal factors such as gestational diabetes mellitus (GDM) 74 
and preeclampsia, which are often observed in women with greater pre-pregnancy BMI [3]. 75 
GDM and preeclampsia are serious and pervasive obstetric complications. Recently, prevalence rates for 76 
GDM and preeclampsia have risen due to lifestyle changes [4], including later pregnancy age, sedentary lifestyle, 77 
and increased fast food consumption. GDM is a condition in pregnancy characterized by carbohydrate intolerance 78 
[5]. GDM affects an estimated 4.6 to 9.2% of pregnancies in the United States [6] with some reports showing a 79 
higher prevalence in minority women [7]. Preeclampsia is another serious disorder in pregnancy, accompanied by 80 
new-onset of hypertension and proteinuria after the 20th week of gestation or near term [8]. Given that the two 81 
conditions often co-occur, some studies have consider GDM as a risk factor for preeclampsia [9]. 82 
Consequences of GDM and preeclampsia on child health have been well documented. GDM increases the 83 
risk for spontaneous abortion, fetal death [10], abnormal birthweight, and malformations [11]. Recent work, 84 
however, has revealed that the effects of GDM are not only limited to the pre- and neo-natal period, but have a 85 
myriad of lasting impacts that persist into later childhood, including neurodevelopmental deficits [12], 86 
neuropsychiatric morbidities [12-13],  physical health outcomes, including metabolic syndrome [14], type 2 diabetes 87 
(T2DM), and obesity [12, 15].  88 
Metabolic syndrome and its sequelae is one of the most notable consequences of GDM [16]. Metabolic 89 
syndrome – which predisposes an individual to cardiac disease and T2DM – refers to an array of conditions 90 
including hypertension, hyperglycemia, large waist circumference, and low HDL cholesterol [17]. 91 
Mechanistically, GDM is believed to impact metabolic imprinting, such that it alters the metabolic milieu and 92 
escalates the risk for T2DM among the offspring and for obesity in childhood and in adolescence [18-19]. 93 
Moreover, pregnancies complicated by GDM may result in excess glucose that goes in the fetal circulation, 94 
leading to macrosomia [20]. As such, the putative fate of offspring born to mothers with GDM is thought to be 95 
high BMI and a greater chance of developing metabolic syndrome. Hyperglycemia due to GDM has been reported 96 
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to increase risk for obesity in children at age 5-7 years-old, although treatment greatly attenuated the risk [18]. To 97 
date, studies examining maternal GDM’s effect on offspring growth trajectory have been sparse and largely 98 
inconsistent. Nevertheless, it is notable that infants born to mothers with GDM can either be small for gestational 99 
age, normal birth weight, or macrosomic [21-23] depending on the degree of glycemic control [24], medical 100 
comorbidity, and maternal pre-pregnancy weight. Given these findings, GDM may not be the sole determinant to 101 
the increased risk of macrosomia and subsequent high BMI or obesity; other neonatal complications that are 102 
present in the pregnancy can also play a role [10].  103 
Similarly, severe preeclampsia is associated with multitudinous biomedical problems, including 104 
hypertension, proteinuria, eclampsia, neurocognitive dysfunction, liver damage, pulmonary edema, and diabetes 105 
mellitus [24]. Fatalities resulting from these symptoms are not limited to mothers, but may extend to the child/fetus 106 
[25-26]. The primary consequence of preeclampsia on the fetus is malnourishment via utero-placental vascular 107 
insufficiency hypoxia, which restricts nutrient and oxygen supplies from the placenta to the fetus [27]. Subsequently, 108 
this leads to various perinatal and neonatal problems, including fetal growth restriction (FGR) [27-29], emergency C-109 
section [29], reduced birth weight [29], and increased acute respiratory distress syndromes postnatally [28]. 110 
Preeclampsia has historically been considered a predictor for later maternal metabolic syndrome [30], but recent 111 
evidence shows that its effects extend to the offspring, as individuals born to mothers with preeclampsia exhibit 112 
increases in blood pressure [31-33]. Although the long-term health and developmental consequences of exposure to 113 
maternal preeclampsia for the surviving child are relatively unexplored, there is evidence for suboptimal 114 
neurocognitive development in addition to FGR, an increase in BMI [34], and childhood obesity [35-36] among 115 
infants of mothers with preeclampsia. 116 
Despite the growing frequency of comorbid GDM and preeclampsia [37-38], to date, little research has 117 
examined the consequences of GDM and preeclampsia on child health simultaneously, especially with obesity. 118 
Among the limited existing work, Kvehaugen and colleagues reported that pregnancies complicated by both GDM 119 
and preeclampsia compared to uncomplicated pregnancies resulted in a higher proportion of offspring that were 120 
overweight at ages 5-8, but group differences did not reach significance [39].  121 
Because the increased prevalence of comorbidity for GDM and preeclampsia coincides with the greater 122 
occurrence of childhood obesity in recent years, it becomes increasingly important to examine the growth trajectory 123 
of infants exposed to GDM and preeclampsia solely as well as jointly throughout development for early detection 124 
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and prevention. Yet, there is a conspicuous paucity of work in this area, with most studies being cross-sectional or 125 
had follow-up periods without including early and mid-childhood. As both GDM and preeclampsia are known risk 126 
factors for suboptimal child development, it is valuable to evaluate the degree to which those conditions collectively 127 
influence BMI developmental trajectory among children of mothers with the two conditions. As such, the goals of 128 
the study are: 1) to investigate the major effect of GDM and preeclampsia on the trajectory of child BMI between 129 
ages 18 and 72 months, and 2) to further evaluate whether the trajectory of BMI by GDM is moderated by 130 
preeclampsia. It was hypothesized that a) GDM status would influence child BMI, such that children born to mothers 131 
with GDM would have higher BMI as they grow than their counterpart, and b) there would be a substantially steeper 132 
trajectory of linear increase in BMI among offspring of mothers with both GDM and preeclampsia.  133 
Method 134 
The current longitudinal investigation was based on 356 mother-child dyads contacted for annual follow-135 
up. Mothers were originally recruited from prenatal clinics in metropolitan New York. Exclusion criteria included 136 
multiple pregnancy, significant congenital anomalies, neurological dysfunction, fetal chromosomal anomalies, 137 
and HIV positivity. Their children were then invited to the lab for annual assessments. Details of the full cohort 138 
can be found elsewhere [40]. From the total sample, 302 (52.3% boys; 47.7% girls) had information on both 139 
obstetric complications including GDM (n=26), preeclampsia (n=24) and multiple assessments. BMI data was 140 
assessed at a maximum of 6 time points (18, 24, 36, 48, 60, and 72 months). Because participants came in for their 141 
assessments as they aged, sample sizes for each assessment time differed: there were 76 children at 18 months, 142 
218 at 24 months, 162 at 36 months, 121 at 48 months, 50 at 60 months, and 20 at 72 months.  143 
Measures 144 
Child Growth Measures         145 
 Height and weight were measured during each assessment by a research staff member without 146 
knowledge of the mother’s obstetric complication status. For height, the child was asked to stand in front of the 147 
growth chart with his/her back straight and feet against the wall. Height was collected by measuring the line that 148 
the child’s head reached and was recorded in centimeters (cm). For weight, the child was asked to step on the 149 
scale barefoot facing outwardly, and weight was collected and recorded in kilogram (kg). BMI was then 150 
calculated using the following formula:  151 
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BMI = weight (kg)/[height (cm) x height (cm)].  152 
Gestational Diabetes Mellitus (GDM) status       153 
 GDM was defined as glucose intolerance with the first onset during pregnancy, determined by a glucose 154 
tolerance test through the woman’s medical practitioner, and ascertained through medical record review 155 
throughout pregnancy (no=0, yes=1). 156 
Preeclampsia status          157 
 Preeclampsia was determined from the obstetric record via participant medical chart review prospectively 158 
during pregnancy (no=0, yes=1). Defined as having high blood pressure (140/90mm Hg) and proteinuria (>300 mg via 159 
24-hour urine collection) after the 20th week of pregnancy.  160 
Demographics/covariates         161 
 Maternal demographic information including age, education, and parity, were collected via self-162 
administered interview. Information on sex, birthweight (BW), gestational age (GA), and body length in 163 
centimeter of the child was collected by a nurse at delivery. Ponderal index was calculated using birthweight and 164 
body length at birth [(birthweight x 100) ÷ (birth length)3]. Demographics of the sample can be found in Table 1.   165 
Statistical Analyses 166 
Hierarchical linear modeling (HLM) was selected to assess how GDM and preeclampsia influenced 167 
changes in child BMI and their trajectories. This was followed by the model with GDM, preeclampsia, and 168 
interaction of the two. Age was centered at 18 months, meaning that the intercept represented the average BMI 169 
when children were 18 months-old. The Level-1 Model was designed to characterize the trajectories (both linear 170 
and quadratic) of BMI changes across six time points ranging from 18 to 72 months. All models in the analysis 171 
were corrected for non-normal distributions of level 2 residuals by applying the full maximum likelihood 172 
estimation with robust standard errors [41]. 173 
Model 1: Change in BMI over time without predictors  174 
Model 1 was designed to characterize the trajectories of BMI across 6 time points. We first tested a model of 175 
linear change (a). As BMI may not display a linear change, we tested for curvilinearity in the linear trajectory for BMI 176 
by adding a quadratic term for age to the model (b). Furthermore, test of relative model fit was computed by 177 
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comparing the deviance statistics of both the linear and quadratic models (Table 2). The quadratic model was retained 178 
if it yielded a significant reduction in deviances according to the Chi-square difference test. In Model 1a, BMI is a 179 
function of an intercept plus a linear effect for age. In Model 1b, BMI is a function of an intercept plus a linear and 180 
curvilinear effects for age. The model equations are as follows: 181 
Linear Model (Model 1a): 182 
Level-1 183 
BMIij = β0j + β1j * (Ageij) + rij  184 
Level-2 185 
β0j = γ00 + u0j 186 
β1j = γ10 + u1j 187 
Quadratic Model (Model 1b): 188 
Level-1 189 
BMIij = β0j + β1j * (Ageij) + β2j * (Ageij)2 + rij  190 
Level-2 191 
β0j = γ00 + u0j 192 
β1j = γ10 + u1j 193 
β2j = γ20 + u1j 194 
Model 2: Predictors of intercepts and slopes 195 
We examined whether GDM and preeclampsia, and their interaction explained significant variance in mean 196 
intercept or slope of child BMI. If BMI displayed neither linear nor quadratic change over time, predictors were added 197 
to calculate the main effects only models. Child sex, BW, GA, marital status, maternal age, maternal education, and 198 
parity were included as covariates in modeling the predictors of change in BMI. 199 
Linear Model (Model 2a): 200 
Level 1 201 
BMIij = β0j + β1j * Ageij + rij 202 
Level 2 203 
β0j = γ00 + γ01 * (GDMj) + γ02 * (preeclampsia j) + γ03 * (GxPj) + γ04 * (Child sexj) + γ05 * (Child-BWj) + 204 
γ06 * (Child GA) + γ07 * (marital statusj) + γ08 * (parityj) + γ09 * (maternal agej) 205 
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β1j = γ10 + γ11 * (GDMj) + γ12 * (preeclampsiaj) + γ13 * (GxPj) + γ14 * (Child sexj) + γ15 * (Child BWj) 206 
+γ16*(Child GA) + γ17 * (marital statusj) + γ18 * (parityj) + γ19 * (maternal agej) 207 
β2j = γ20 + γ21 * (GDMj) + γ22 * (preeclampsiaj) + γ23 * (GxPj) + γ24 * (Child sexj) + γ25 * (Child BWj) + 208 
γ26*(Child GA) + γ27 * (marital statusj) + γ28 * (parityj) + γ29 * (maternal agej) 209 
Quadratic Model (Model 2b): 210 
Level 1 211 
BMIij = β0j + β1j * Ageij + β1j * (Ageij)2 + rij 212 
Level 2 213 
β0j = γ00 + γ01 * (GDMj) + γ02 * (preeclampsiaj) + γ03 * (GxPj) + γ04 * (Child sexj) + γ05 * (Child BWj) + 214 
γ06*(Child GA) + γ07 * (marital statusj) + γ08 * (parityj) + γ09 * (maternal agej) + u0j 215 
β1j = γ10 + γ11 * (GDMj) + γ12 * (preeclampsiaj) + γ13 * (GxPj) + γ14 * (Child sexj) + γ15 * (Child BWj) + 216 
γ16*(Child GA) + γ17 * (marital statusj) + γ18 * (parityj) + γ19 * (maternal agej) + u1j 217 
β2j = γ20 + γ21 * (GDMj) + γ22 * (preeclampsiaj) + γ23 * (GxPj) + γ24 * (Child sex) + γ25 * (Child BW) + 218 
γ26*(Child GA) + γ27 * (marital statusj) + γ28 * (parityj) + γ29 * (maternal agej) + u2j 219 
Missing data  220 
HLM provided a robust method of dealing with the missing data and yields parameter estimates for 221 
missing time points for dependent variable data (BMI) at level 1 (i.e., within subject variability) but not for 222 
predictor variables at level 2 (i.e., between subject variability). Rather than removing a portion of the sample by 223 
using repeated-measures analysis, we leveraged this central methodological strength of HLM and generated 224 
estimates for missing data at certain time points. There were no missing data at level 2.  225 
Results 226 
Model selection           227 
 We modeled BMI as a function of the intercept with the linear and quadratic effect of age to explore 228 
whether the mean intercepts (BMI at 18 months) or slopes (rate/direction of change of BMI over time) differ 229 
between offspring of mothers with the obstetric risks (GDM and preeclampsia) and without them. We built four 230 
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models and chose our best fitted model. Changes indices for model fit for the two models (Model 1 and Model 2) 231 
in two growth trajectories (linear and quadratic) are listed in Table 2.   232 
We first tested our intercept only model (Model 1) with a linear (a) vs. quadratic (b) slope. Model 1a 233 
predicted a β1 of -.57 (95%CI -.73, -.41, p <.001, t-ratio = -6.68) with a X2 deviance score of 1945.56 with a 234 
degree of freedom of 6. Model 1b predicted a β1 (linear slope) of -1.20 (95%CI -1.60, -.80, p <.001, t-ratio=-5.99) 235 
and a β2 (quadratic slope) of .04 (95%CI .10, .26, p<.001, t-ratio=3.96) with a X2 deviance score of 1927.81 with a 236 
degree of freedom of 10. As seen in Table 2, this indicates that the model with a quadratic term to predict BMI is 237 
significantly better than the model with only a linear term) [X2(4) = 17.75, p=.001]. Figure 1 shows our preferred 238 
model (Model 1b). 239 
Following Model 1, we tested Model 2 with intercept and predictors (GDM, preeclampsia, and the 240 
interaction) in the linear model (Model 2a) and quadratic model (Model 2b). Model 2a predicted a X2 deviance 241 
score of 1891.98 with a degree of freedom of 25, whereas the quadratic model predicted a X2 deviance score of 242 
1869.79 with a degree of freedom of 39. Since Model 2b was found to be only marginally [X2(14)=22.19, p=.075] 243 
better than Model 2a, we chose Model 2a as a better model, presented in Figure 2. Finally, between Model 1b and 244 
Model 2a, Model 2a was selected as the final model because it was significantly better fitted [X2(15)=35.83, 245 
p=.002]. 246 
Trajectories of BMI predicted by GDM, preeclampsia, and the interaction in our final model  247 
 Our final model (Model 2a) with an intercept and predictors (GDM, preeclampsia, and the interaction) 248 
shows that there were no significant effects of GDM (β=-.014, 95%CI -1.33, 1.30, p=.75, t-ratio=-.31), 249 
preeclampsia (β=-.84, 95%CI -1.94, .17, p=.14, t-ratio=-1.47), and the interaction of the two (β=.56, 95%CI -2.87, 250 
3.79, p=.74, t-ratio=.54) in predicting intercept for BMI. However, preeclampsia (β=.65, 95%CI .11, 1.19, p=.02, 251 
t-ratio=3.15) and the interaction of the two (β=-1.24, 95%CI -2.33, -.15, p=.02, t-ratio=-2.24) were significant and 252 
GDM (β=.45, 95%CI -.05, .95, p=.07, t-ratio = 1.79) was marginally significant in the linear model. Figure 2 253 
shows the significant interaction between GDM and preeclampsia, where BMI of children born to mothers with 254 
both GDM and preeclampsia steadily increased over time whereas BMI of children with only GDM and only 255 
preeclampsia slowly decreased over time, and BMI of children with neither GDM nor preeclampsia decreased 256 
more over time. 257 




The current study has two main findings: First, children from pregnancies complicated by preeclampsia 259 
are more likely to have significantly greater childhood BMI. The pattern is the same with GDM, but it was only 260 
marginally significant. Second, children born to mothers with comorbid of GDM and preeclampsia had a greater 261 
chance and upward trajectory of having greater BMI as they grow. Overall, our findings were consistent with 262 
prior reports demonstrating associations between GDM and an increased risk for childhood obesity later in 263 
childhood [18]. The study also extended our knowledge by providing initial evidence that children of mothers 264 
with both GDM and preeclampsia had a greater propensity of obesity as evidenced by a significant and upward 265 
BMI trajectory. Interestingly, children born to mothers with preeclampsia only had relatively stable BMI across 266 
the examined time period, albeit significantly higher than children born from healthy mothers. Fetuses of mothers 267 
with preeclampsia may have had to develop in the womb with less blood flow, potentially meaning their bodies 268 
would have to do more with less means. As they grow up, their bodies may be used to not having as much, and 269 
thus hold onto extra weight more efficiently. Alternatively, the effects of increasing trajectory in preeclampsia 270 
only may not emerge until later ages when adiposity rebound occurs. While the BMI we have observed during this 271 
period did not reach the alarming level of childhood obesity, it is important to see the longer term patterns of BMI 272 
changes among children whose mothers had biomedical complications such as GDM and preeclampsia, which are 273 
known to influence endocrine and adipose tissue-derived factors on the hypothalamic-pituitary-gonadal (HPG) 274 
axis functioning [42].  275 
Prior studies have looked at both obstetric risks independently, but to the best of our knowledge, this is 276 
the first study to examine the combination of both GDM and preeclampsia on child BMI, which are often co-277 
occurring obstetric conditions. Indeed, the presence of either complication has impacts on child health, but we 278 
illustrate that their co-occurrence substantially increases child BMI trajectory. Moreover, we covered a longer 279 
period of growth trajectory (e.g., 18-72 months). Based on our results, having GDM or preeclampsia does affect 280 
child BMI trajectory to some extent, but the combination of the two is especially effectual in driving higher child 281 
BMI. The present findings have important implications for maternal health in pregnancy and later childhood 282 
health outcomes.  283 
 284 
GROWTH TRAJECTORY IN CHILDREN 
 
11 
The current study also has limitations. First, the study has a relatively small sample size. As prevalence 285 
for GDM and preeclampsia was 12% and 18% respectively, with 7 cases having both diagnoses, cases with 286 
positive diagnoses were small. Thus, our results should would be interpreted with caution. However, it is known 287 
that statistical strategy with repeated measures increases statistical power. While preliminary, our findings provide 288 
guidance for future studies with a larger sample size. Second, there was no information on GDM such as the level 289 
of glycemic control (e.g., A1C levels) and preeclampsia (type and severity) during pregnancy, as well as 290 
information on whether or not mothers with the condition underwent treatment or intervention. Evidence suggests 291 
that glycemic control can impact offspring weight [43]. Third, there was no data on child diet and physical 292 
activity. Dietary intake and physical activity level play a role in weight changes during childhood and adolescence 293 
[44]. Even as early as infancy, intensive breastfeeding from birth to 12 months has been found to be associated 294 
with lower weight gain and slower ponderal growth in children born to mothers with GDM [45]. Fourth, BMI 295 
measurements in our study were based on height and weight measured by the same equipment by two research 296 
staff in order to avoid errors due to the measurements by different equipment. However no other measurement 297 
methods (e.g., calipers or 3D body imaging) were used to increase the validity of the BMI measure. Relying on 298 
one method may have reduced the validity of the BMI scores. Taken together, future work would benefit with 299 
obtaining information on those factors, including the influence of glycemic control, management and treatment of 300 
obstetric complications, child diet or activity level, and collect height and weight measures with a minimum of 301 
two types of equipment.    302 
Despite these caveats, the present findings from this research help us better understand the effect of 303 
maternal GDM and/or preeclampsia on subsequent child BMI. This is the first longitudinal investigation that has 304 
examined the role of both GDM and preeclampsia on child BMI simultaneously at multiple follow-up 305 
assessments. When possible, future studies should opt to design longitudinal investigations to replicate our 306 
longitudinal findings to help researchers confirm at what age the effects of obstetric complications emerge in 307 
children and their developmental trajectory. Given our conclusion that GDM and preeclampsia could be used as a 308 
marker for childhood weight problems (overweight and obesity) and the identification of high-risk children, 309 
expectant mothers and health professionals should monitor patients and their offspring more closely for a longer 310 
period of time even after the birth, if their pregnancies are complicated by these two conditions. For example, 311 
prescription Aspirin of 150 milligrams daily from 11 up till 36 weeks gestation substantially decreases the risk of 312 
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child obesity up until 72 months of age [46]. Because GDM and preeclampsia are common and manageable 313 
obstetric risks, it is hoped that gaining more knowledge on its long-term impact can inform and encourage 314 
individuals to acknowledge the importance of their management and treatment during pregnancy as one of the 315 
most cost-effective methods of childhood obesity prevention.  316 
  317 
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Figure Captions 318 
 319 
Fig 1. Growth trajectory of child BMI between 18 and 72 months – Intercept only model with curvilinear growth 320 
(Model 1b) 321 
 322 
 323 
Fig 2. Growth trajectory of child BMI between 18 and 72 months of age – Intercept and predictors (GDM, 324 
preeclampsia, and the interaction of the two) (Model 2a – linear model) 325 
 326 
 327 
NB: BMI = body mass index 328 
0 = absence; 1 = presence 329 
  330 
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Table 1R. Maternal and child demographics and obstetric characteristics, and body mass 331 
index (BMI) in participants (N=302) 332 
Maternal characteristics 
Mean (SD) 
 Child characteristics 
Mean (SD) 
Age at child’s birth (years)  27.74 (6.07)  Birth outcomes    
Pre-pregnancy BMI  26.13 (6.13)  Birthweight (grams)  3,224.68 (607.38) 
   Gestational age (weeks)   38.78 (2.18) 
Educational attainment, N (%)        Ponderal index   25.89 (9.23) 
Elementary school     8 (2.6)    
Some high school   36 (11.9)  Fetal growth, N (%)  
High school diploma/ GED   65 (21.5)  Small for gestational age   24 (8.9) 
Some college   81 (26.8)  Normal for gestational age 224 (82.6) 
Associate degree   34 (11.3)  Large for gestational age   23 (8.5) 
Bachelor’s degree   44 (14.6)    
Graduate degree   34 (11.3)  NICU admission, N (%)   40 (13.24) 
     
Marital status, N (%)        Gender, N (%)       
Married 124 (41.0)  Male   158 (52.3) 
Common law marriage   16 (5.3)  Female   144 (47.7) 
Single 160 (53.0)    
Divorced/Separated     2 (0.7)  Body Mass Index (BMI)    Mean (SD) 
   18 months   18.33 (2.14) 
Race, N (%)        24 months   18.01 (2.16) 
White   53 (17.5)  36 months   16.63 (1.55) 
Black   66 (21.9)  48 months   16.43 (1.99) 
Hispanic 153 (50.7)  60 months   16.21 (2.13) 
Asian   25 (8.3)  72 months   15.63 (1.71) 
Others     5 (1.7)    
     
Substance use during pregnancy, N (%)            
Cigarette    34 (11.3)    
Cannabis    20 (6.6)    
Alcohol   19 (6.3)    
Other substances   15 (5.0)    
     
Biomedical illness, N (%)       
Gestational diabetes myelitis   26 (8.6)    
Preeclampsia   24 (7.9)    
     
NB:  N may vary due to missing values 
 333 
  334 
  335 
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Table 2.  Model comparisons with X2 deviance score in the model with degrees of freedom 336 
and associated p-value 337 
 Linear model (a) 
X2 deviance (df) 
Quadratic model (b) 
X2 deviance (df) 
∆X2 (∆df), p-value 
(within Models 1 or 2) 
Model 1 1945.56 (6) 1927.81 (10) 17.75 (4), p = .0013 
Model 2 1891.98 (25) 1869.79 (39) 22.19 (14), p = .075 
∆X2 (∆df), p-value  
(Models 1 vs 2) 
53.58 (19), p < .0001 58.02 (29), p = .001 
 
NB: ∆X2 (∆df), p-value for Model 1b vs Model 2a was X2(15) = 35.83, p =.002.  Model 2a 338 
was selected as the best model. 339 
 340 
  341 
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